Company intelligence / Profile preview
Suzhou NeuPharma
Suzhou, Jiangsu, Chinaneupharma.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
Suzhou NeuPharma has advanced several novel small molecule oncology drug candidates into the clinic, with olafertinib in Phase 3 for EGFR-mutant non-small cell lung cancer, uplarafenib in Phase 2 for BRAF-mutant glioblastoma, and additional programs in earlier stages targeting Na/K-ATPase.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Suzhou NeuPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou NeuPharma.